Ivermectin pharmacokinetics describes what happens to the drug after it enters the body: how it is absorbed, distributed, metabolized and eliminated. For human oral ivermectin tablets, U.S. labeling provides clinical observations about plasma concentrations, peak timing, the influence of food and the principal routes of drug removal. Those measurements describe exposure under particular study conditions. They do not establish a dose for an individual, prove effectiveness against a given infection or show when an individual person should expect a clinical response.
The terms often used in pharmacokinetic studies have distinct meanings. Cmax is the highest measured plasma concentration; Tmax is the time at which it occurs; AUC describes total measured exposure over a specified interval; and elimination half-life describes a decline in concentration during a particular phase. U.S. tablet labeling reports a peak at about four hours after a studied single oral dose and an approximate plasma half-life of 18 hours. Those figures belong to the studied oral product and conditions, not to every ivermectin formulation or patient circumstance.
Ivermectin is also sold in human topical products, including prescription cream 1% for inflammatory rosacea lesions and OTC lotion 0.5% for head lice. Their patterns of skin absorption and systemic exposure cannot be inferred simply from tablet data or from the percentage printed on a tube or bottle. This guide follows the oral absorption-to-elimination sequence first, then identifies what formulation-specific studies do—and do not—tell us about topical products. Product instructions, approved indications and safety considerations remain separate questions.
Following ingestion of an oral tablet, ivermectin must become available for absorption through the gastrointestinal tract before it can be measured in systemic blood samples. Researchers collect plasma samples at specified times after administration and use the resulting concentration-time profile to describe exposure. The rising portion of the curve reflects absorption together with distribution and removal processes that are already occurring. It is therefore too simple to treat the moment a medicine enters the stomach as the moment its blood concentration reaches a maximum.
U.S. oral-tablet labeling describes two studies in fasting healthy volunteers who received a single studied 12 mg oral dose. The mean peak concentrations measured for the major ivermectin component, H2B1a, were 46.6 and 30.6 ng/mL in the two studies, at approximately four hours after administration. The differing average peaks and the ranges around them illustrate why a study mean should not be treated as a person's expected result. Importantly, these observations are reported measurements from a particular research setting, not a suggested tablet quantity for self-treatment.
Tmax and Cmax are pharmacokinetic observations rather than treatment promises. A peak measured near four hours does not prove that every clinical effect begins at four hours, nor does it show how long an antiparasitic effect persists. The studied outcome, the target organism and patient-specific clinical assessment matter separately. Readers interested in exact marketed human tablet strengths can review 3 mg tablet identification and 6 mg tablet identity and approval status; those product strengths should not be confused with the total amount studied in a PK experiment.
| Oral PK measure | Label-based observation or definition | What it does not establish |
|---|---|---|
| Single-dose study setting | Fasting healthy volunteers receiving a studied 12 mg oral dose | An appropriate regimen for an individual patient |
| Tmax | Peak plasma concentration at approximately 4 hours in the cited oral studies | Exact onset or duration of clinical benefit |
| Cmax | Mean major-component peaks of 46.6 and 30.6 ng/mL in two studies | A universal concentration for all individuals or strengths |
| Exposure across studied doses | Plasma concentration generally increased approximately proportionally with oral dose under studied conditions | Permission to extrapolate to unstudied regimens or conditions |
| Oral plasma half-life | Approximately 18 hours according to human tablet labeling | The time at which treatment must be repeated or the drug is completely gone |
Bioavailability refers to the portion of an administered drug that reaches systemic circulation. With an oral product, the composition of a meal, how a medicine moves through the gastrointestinal tract and drug-specific absorption characteristics may influence the resulting exposure. A concentration-time curve can therefore change without any change in the active ingredient printed on a tablet label. Pharmacokinetic findings are reported in the context of the conditions used to obtain them, which is why food-related results should be read together with the study design.
Tablet labeling describes a research comparison involving a 30 mg oral dose given after a high-fat meal versus the same studied amount in a fasted state. In that experiment, bioavailability was approximately 2.5 times higher after the high-fat meal. This is a finding from the specified investigation, not a recommended dose, a universal multiplier for every meal or an invitation to increase exposure. It must not be used to infer that taking additional tablets, changing meal timing or using fatty food will improve the effectiveness of a prescription.
The distinction matters because an observed change in systemic exposure does not by itself establish better outcomes or a safer treatment. Food advice must come from the applicable product label and the prescribing clinician rather than from a reader's interpretation of one research experiment. Even when a pharmacokinetic result is reproducible, clinicians consider it alongside the labeled indication, patient context and other medicines. This page explains the PK evidence and intentionally does not convert it into personal administration instructions.
Once ivermectin reaches the bloodstream, the measured plasma concentration reflects drug present in that sampled compartment at a given time. Distribution is the broader process by which drug moves among plasma, tissues and other compartments. A plasma number is useful because it can be collected consistently in research, but it is not a map of every tissue concentration. The extent of distribution depends on chemical properties, binding to blood proteins and physiologic barriers, as well as the conditions of the study.
Ivermectin is highly protein-bound in human in-vitro assessments cited in topical cream labeling, principally to albumin. This detail helps explain why measured total plasma concentration should not automatically be equated with the unbound fraction available for movement into tissues. Nevertheless, a binding observation from an in-vitro method does not provide a patient-specific tissue concentration or a complete oral distribution model. It should be interpreted as one part of a larger PK picture, not as a numeric promise about drug activity in any organ.
Questions about central nervous system exposure require particular care because transport barriers and susceptibility can affect safety. A mechanistic discussion of parasite ion channels belongs on the separate ivermectin mechanism-of-action page; the distribution question here concerns what the body does with the drug. For adverse reactions, interactions and unusual risk scenarios, consult the cross-form ivermectin safety overview. Neither a blood concentration nor a tissue-distribution hypothesis can substitute for a clinical evaluation.
Metabolism is the biochemical conversion of a substance into other molecules, commonly called metabolites. Oral ivermectin labeling identifies the liver as an important site of metabolism. In-vitro experiments using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the principal cytochrome P450 enzyme involved. Smaller contributions from CYP2D6 and CYP2E1 were observed in some laboratory methods. This is evidence about enzyme involvement, but the magnitude of an individual interaction cannot be calculated merely from naming a CYP enzyme.
A medication may influence metabolism if it inhibits or induces an enzyme, changes transport processes or affects other determinants of exposure. Whether that influence is clinically important depends on the interacting product, the level and timing of exposure and the available human evidence. A CYP3A4 substrate is not automatically incompatible with every other drug processed through the same enzyme. Equally, a reassuring laboratory result does not rule out all clinically significant interactions in real-world care.
For that reason, pharmacists and clinicians review the complete medication list, including prescription medicines, nonprescription products and supplements, when evaluating an oral prescription. They may also consider hepatic function and the indication being treated. This page does not rank interacting medicines, predict an individual's blood level or propose dose adjustments. Those decisions belong to a qualified clinician using current labeling and the specific patient's circumstances.
Elimination is the overall reduction of drug from the body through metabolism and excretion. In U.S. human oral-tablet labeling, ivermectin and/or its metabolites are reported to be excreted almost exclusively in feces over an estimated 12-day period, with less than 1% of the administered dose recovered in urine. These observations describe reported recovery pathways; they do not mean that unchanged active drug remains at a therapeutic concentration in the body for 12 days, nor do they mean that kidney-related questions can always be ignored.
The approximate oral plasma half-life listed for ivermectin is 18 hours. Half-life describes how long it takes for concentration to decline by one half during the relevant kinetic phase. It is not identical to the time a drug takes to leave the body completely. It also should not be used as a simple countdown to parasite clearance, symptom resolution or the appropriate interval before another prescription is considered. Those are separate clinical questions affected by the disease and treatment plan.
In interpreting a half-life estimate, the formulation and sampling period are essential. Values may differ when absorption continues over time, as happens with some topical products, or when researchers examine a different phase of the concentration curve. That is one reason not to place the oral 18-hour figure beside a cream-specific terminal half-life and conclude that one product is proportionally more potent or lasts longer in its intended tissue. Half-life alone cannot establish comparative clinical effectiveness.
A concentration-time curve is created by plotting measured drug concentration against time after administration. Its upward slope reflects entry into the sampled circulation, its maximum provides a measured Cmax at Tmax, and the subsequent decline reflects distribution and elimination in combination with any continuing absorption. Researchers may calculate AUC by integrating the concentrations over a defined interval. An AUC value without an interval, sample population or route of administration is incomplete information.
Two regimens could have different Cmax values while producing similar measured AUC, or similar peak levels with different overall exposure. Neither situation automatically proves one regimen produces better clinical outcomes. The shape of a curve is also influenced by differences between people, the meal conditions, sampling schedules and formulation characteristics. Averages can summarize a study while concealing substantial individual variability, so the ranges and population description matter as much as the mean.
For oral ivermectin, published label data provide an empirical starting point rather than a complete individual prediction model. Readers comparing a generic oral product with a reference product should distinguish regulatory bioequivalence evaluation from the idea that every person has identical plasma levels. Similarly, a concentration curve is not a substitute for a clinical outcome study or a basis for choosing between products designed for different routes of administration.
| PK concept | Question answered | Interpretation boundary |
|---|---|---|
| Absorption | How does ivermectin enter systemic circulation from the dosage form? | Route-specific; tablet observations cannot describe a cream or lotion automatically |
| Tmax | When was the highest sampled plasma concentration reached? | Not identical to when symptoms improve |
| Cmax | How high was the sampled peak in a defined study? | Not a standalone measure of antiparasitic success |
| AUC | What was the integrated exposure over the specified time interval? | Requires a stated interval, formulation and study context |
| Half-life | How quickly does plasma concentration decline in the reported phase? | Not a self-treatment interval or a complete clearance clock |
| Between-person variability | How much might observations differ across study participants? | Population averages cannot set a patient-specific regimen |
A prescription ivermectin cream is applied to the skin rather than swallowed, so systemic drug exposure depends on absorption through the treated skin and the way the formulation is used. U.S. Soolantra cream 1% labeling describes a study involving 15 adults with severe papulopustular rosacea who applied 1 g of cream once daily. After two weeks of treatment, mean peak plasma concentration was 2.10 ng/mL with a standard deviation of 1.04 ng/mL. This is a topical-use observation in a small defined population, not a direct counterpart to the oral single-dose studies.
The same cream labeling reports a mean Tmax of 10 hours with a standard deviation of eight hours under that study's conditions. Following once-daily skin application for 28 days, the apparent terminal half-life averaged about 6.5 days. Such a terminal value can be influenced by the continued movement of drug from skin into systemic circulation; it must not be taken to mean that the skin cream has the same disposition after oral dosing or that its treatment effect lasts for that exact interval.
In longer topical studies, labeling reports no plasma accumulation over 52 weeks under the evaluated conditions. That statement does not mean zero systemic absorption, nor does it generalize to misuse or to other skin products with different ingredients. The relevant question for a reader is how a specific registered cream was evaluated. Indication, age limits, local tolerability and prescription access are described more fully on the product pages, while this section stays with pharmacokinetic interpretation.
Human ivermectin lotion 0.5% is a head-lice product used on the scalp and hair, and its regulatory labeling and instructions differ from those for rosacea cream. A lotion intended for a brief application followed by rinsing does not have the same exposure scenario as a cream used on facial skin over repeated days. Even if both preparations contain ivermectin, a percentage concentration is not a measure of how much active drug enters the bloodstream. The amount used, application site, contact time and formulation all matter.
Published pediatric evaluations of ivermectin lotion found low, measurable plasma concentrations after appropriately studied topical use. Such results support the need to distinguish limited systemic exposure from an assertion that absorption is literally zero. The children evaluated, methods used and timing of blood collection were specific to the lotion program; applying those numbers to the cream, to an oral dose or to a different product would be misleading. The cream-versus-lotion comparison addresses the different labeled purposes and dispensing rules rather than making an invalid dose-equivalence claim.
This is also why an OTC product cannot be substituted for a prescription tablet merely because it shares the active ingredient, and why a 1% cream is not a higher-strength version of a 0.5% head-lice treatment. Each human formulation was developed and assessed in its own setting. Veterinary ivermectin preparations introduce additional formulation and safety concerns and should not be used as alternatives to approved human medicines.
Pharmacokinetics is necessary for understanding a medicine, but it is one component of clinical evidence. Plasma measurements do not independently establish whether an infection is present, which parasite is involved or whether ivermectin is the appropriate medicine. For example, the labeled oral use in intestinal strongyloidiasis has a different evidence and regulatory context from off-label oral use for scabies. Pharmacokinetic similarities cannot convert an off-label condition into an FDA-approved indication.
For a prescribed oral product, interpretation also depends on the official label, concurrent medicines, patient characteristics and any needed clinical monitoring. Half-life, food effects or a concentration from a published study should never be treated as instructions to alter a prescribed regimen. The broader U.S. prescription guide explains how a clinician's authorization relates to pharmacy dispensing, without attempting to reproduce pharmacokinetic modeling as a purchasing checklist.
When evaluating a research article or product claim, it helps to ask four questions: which formulation was studied, which population received it, what exposure measure was used and whether the conclusion concerns a laboratory parameter or an actual clinical outcome. Keeping these distinctions clear prevents the familiar errors of treating an oral half-life as an effect-duration promise, comparing unaligned topical and oral concentrations or inferring efficacy from exposure alone. The purpose of this page is to make those limits legible, not to suggest that consumers can use PK data to select their own treatment.
It describes absorption, distribution, metabolism and elimination of ivermectin in the body. Researchers use timed blood samples and other measurements to understand systemic exposure under specified conditions. Pharmacokinetics is not the same as the drug's action on parasites or proof that a particular clinical treatment will work.
U.S. oral-tablet labeling reports peak plasma concentrations at approximately four hours after a studied single 12 mg dose in fasting healthy volunteers. That is a study observation, not a universal peak time, a prescribed amount or a prediction about when symptoms will change.
Human oral-tablet labeling gives an approximate plasma half-life of 18 hours. Half-life concerns concentration decline in the studied setting; it does not mean the drug disappears completely after 18 hours or that a dose should be repeated after that period.
A tablet-label pharmacokinetic experiment reported about a 2.5-fold increase in bioavailability after a high-fat meal compared with a fasted state for a studied 30 mg amount. The result is not a general food instruction or a reason to change a prescribed regimen. Follow the actual product labeling and clinician's instructions.
Oral labeling reports that ivermectin and/or its metabolites are excreted almost exclusively in feces over an estimated 12 days, with less than 1% of the administered dose appearing in urine. The recovery period is not equivalent to a therapeutic duration or an exact time when all active drug is gone.
In-vitro investigations in human liver systems identify CYP3A4 as the principal CYP enzyme involved, with smaller contributions from other enzymes under some methods. These findings do not by themselves predict how a specific drug interaction will affect an individual. A clinician or pharmacist must interpret interactions using the full medication context.
Not necessarily. Cmax describes the highest measured concentration in a defined study. Clinical effectiveness depends on the condition, organism, formulation and clinical evidence. A higher observed peak is not an independent guarantee of benefit or safety.
No. The cream has its own systemic absorption and terminal half-life data following application to skin. Those observations arise from a different route, population and dosing schedule. Oral and topical half-life or peak values should not be used to estimate relative effectiveness or choose a regimen.
No absolute zero-absorption claim is justified. Small studies of the head-lice lotion identified low measurable plasma concentrations after topical use. The findings are formulation-specific and do not make the OTC lotion interchangeable with the prescription rosacea cream or human oral tablets.
No. Published population pharmacokinetic measurements cannot determine an individual's dose or the suitability of ivermectin for a diagnosis. Treatment decisions require the approved product information and a clinician's evaluation. The same caution applies to changing tablet strength, food timing or use of a different formulation.